Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing

Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing

Current antiviral therapy fails to cure chronic hepatitis B virus (HBV) infection because of persistent covalently closed circular DNA (cccDNA). CRISPR/Cas9-mediated specific cleavage of cccDNA is a potentially curative strategy for chronic hepatitis B (CHB). However, the CRISPR/Cas system inevitabl...

Full description

Bibliographic Details
Main Authors: Yu-Chan Yang, Yu-Hsiang Chen, Jia-Horng Kao, Chi Ching, I-Jung Liu, Chih-Chiang Wang, Cheng-Hsueh Tsai, Fang-Yi Wu, Chun-Jen Liu, Pei-Jer Chen, Ding-Shinn Chen, Hung-Chih Yang
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Molecular Therapy: Nucleic Acids
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253120300962

Internet

http://www.sciencedirect.com/science/article/pii/S2162253120300962

Similar Items